Drug Trial Radar · NCT02409290
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
588
Actual
Start
Mar 2016
Primary completion
May 13, 2022
Study completion May 2, 2023
Sponsor
- Lead sponsor
- IUATLD, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council; Institute of Tropical Medicine, Belgium; Liverpool School of Tropical Medicine; Rede TB
- First posted
- Apr 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing. Despite the availability and effectiveness of affordable six-month treatments for tuberculosis (TB), the worldwide control of this disease is currently being impacted by the emergence of multidrug resistant TB (MDR-TB). MDR-TB refers to TB that is resistant to at least isoniazid and rifampicin. These are the two most powerful first-line drugs used to treat pulmonary TB. MDR-TB usually develops while a person is taking TB treatment due to either inappropriate treatment or failure of patients to comply with their treatment. This strain of drug-resistant bacteria can also be spread to other people through the air. With the incident rate of MDR-TB on the rise, there is a need to investigate optimal treatment regimens using effective drugs.
Conditions
- MDR-TB
Interventions
Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)Drug
Drug: Locally-used WHO-approved MDR-TB regimen
MoxifloxacinDrug
Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
ClofazimineDrug
Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
EthambutolDrug
Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
PyrazinamideDrug
Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
IsoniazidDrug
Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
ProthionamideDrug
Prothionamide has a bacteriostatic action.
KanamycinDrug
Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
LevofloxacinDrug
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
BedaquilineDrug
Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)Time frame: 76 weeks
Locations
13 sites in 7 countries. Site status is shown where the registry gives one.
Armauer Hanssen Research Institute
Addis Ababa, Ethiopia
St. Peter's Tuberculosis Specializes Hospital
Addis Ababa, Ethiopia
JSC National Center for Tuberculosis and Lung Diseases
Tbilisi, Georgia
BJ Medical College Civil Hospital
Ahmedabad, India
The National Institute for Research in Tuberculosis
Chennai, India
Rajan Babu Institute for Pulmonary Medicine and Tuberculosis
New Delhi, India
Institute of Phthisiopneumology 'Chiril Draganiuc'
Chisinau, Moldova
National Centre for Communicable Diseases
Ulaanbaatar, Mongolia
King Dinizulu Hospital
Durban, South Africa
Helen Joseph Hospital
Johannesburg, South Africa
Doris Goodwin Hospital
Pietermaritzburg, South Africa
Empilweni TB Hospital
Port Elizabeth, South Africa
Makerere University (Mulago Referral Hospital)
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.